Covered, diversified — lumpy quarters, real income. A 5.72% trailing yield from 100 of the highest-yielding stocks in developed markets outside the U.S., at a 0.50% expense ratio, with trailing total return of about 21% over the past year. The payout is funded by the holdings’ dividends, not leverage or options — but budget on the trailing twelve months, not on any single quarter.
Key risk: Concentration: financials are about 37% of the portfolio and Europe about 82% of its regions, so a European bank downturn or a currency swing moves this fund more than a global fund.
Changes if: Trailing-12-month distributions fall for two consecutive quarters, or the expense ratio rises materially. Quarterly lumpiness alone is not a tripwire — the trailing total is.
- ✓Yield check: 5.72% trailing — $2.42 of distributions over the trailing 12 months (Dec. 2025 $0.5919, Mar. 2026 $0.2010, Jun. 2026 $1.1016, Sep. 2026 $0.5298) at the $42.36 close on Oct. 23, 2026.
- !Expense check: 0.50% a year is more than eight times SCHD’s 0.06%. Developed ex-U.S. screening is what the extra fee buys — judge whether it is worth it.
- !Distribution-pattern check: Quarterly amounts swing from $0.20 to $1.10 because the underlying payers cluster their dividends — the income is real, but a single quarter says almost nothing about the run rate; the $2.42 trailing total is the figure to watch.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.